(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/196505 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/IB2025/000110

(22) International Filing Date:
21 March 2025 (21.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,617 22 March 2024 (22.03.2024) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **ALLAN, Bernard**; c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (US). **KO, Brian**; c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (US). **KUMAR, Pawan**; c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (US). **NAZEF, Naim**; c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (US). **PICKENS, Jason**; c/o Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA 02142 (US).

(74) Agent: **YAMAMOTO, Shusaku**; 17th Floor Grand Front Osaka Tower C, 3-1 , Ofuka-cho, Kita-ku, Osaka-shi, Osaka 5300011 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION

sense numbering	5'			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	3'
MOD1	sense			mN	mN	mN	mN	mN	mN	mN	mN	fN	fN	fN	fN	mN	mN	mN	mN	mN	mN	mN	mN	mN	MOD1
	antisense	mN	mN	mN	mN	mN	mN	mN	mN	mN	fN	mN	mN	mN	fN	mN	fN	fN	mN	fN	mN	fN	fN	mN	
MOD2	sense			mN	mN	mN	mN	mN	mN	mN	mN	fN	fN	fN	fN	mN	mN	mN	mN	mN	mN	mN	mN	mN	MOD2
	antisense	mN	mN	mN	mN	mN	mN	mN	mN	mN	fN	mN	mN	mN	fN	mN	mN	fN	fN	fN	mN	fN	fN	mN	
MOD3	sense			mN	mN	mN	mN	mN	mN	mN	mN	fN	fN	fN	fN	mN	mN	mN	mN	mN	mN	mN	mN	mN	MOD3
	antisense	mN	mN	mN	mN	mN	mN	mN	mN	mN	fN	mN	mN	mN	fN	mN	fN	fN	fN	fN	mN	fN	fN	mN	
MOD4	sense			mN	mN	mN	mN	mN	mN	mN	mN	fN	fN	fN	fN	mN	mN	mN	mN	mN	mN	mN	mN	mN	MOD4
	antisense	mN	mN	mN	mN	mN	mN	mN	mN	mN	fN	mN	mN	mN	fN	mN	mN	fN	mN	mN	mN	fN	fN	mN	
antisense numbering	3'	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	5'

FIG. 1

(57) Abstract: RNAi agents (e.g., CYP7A1 RNAi agents) for inhibiting the expression of the CYP7A1 gene, compositions including the RNAi agents conjugated to a targeting moiety, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more RNAi agents (e.g., CYP7A1 RNAi agents). Delivery of the RNAi agent(s) to liver cells in vivo inhibits CYP7A1 gene expression and treats a CYP7A1 disease or a CYP7A1-associated disease.

WO 2025/196505 A2

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*